坎地沙坦对扩张性心肌病患者血清和肽素的影响

Influence of candesartan on serum copeptin in patients with dilated car-diomyopathy

目的研究坎地沙坦对扩张性心肌病患者血清和肽素的影响。方法选择2013年1月~2014年6月在我院就诊的42例扩张性心肌病患者,将其随机分为坎地沙坦组（27例）和常规治疗组（15例）,另设年龄、性别与之匹配的28例健康者作为对照组。采用酶联免疫分析法检测3组患者的血清和肽素水平,另外,常规治疗组和坎地沙坦组在治疗2周后复查。结果扩张性心肌病患者血清和肽素水平较健康者明显升高,差异有统计学意义（P〈0.05）。治疗后,坎地沙坦组血清和肽素水平较治疗前明显下降,差异有统计学意义（P〈0.05）,但常规治疗组血清和肽素水平较治疗前差异无统计学意义（P〉0.05）。结论扩张性心肌病心力衰竭患者血清和肽素水平较健康者升高,而坎地沙坦能明显降低扩张性心肌病心力衰竭患者的血清和肽素水平。

Objective To explore the impact of candesartan on serum copeptin in patients with dilated cardiomyopathy. Methods 42 patients with dilated cardiomyopathy admitted into our hospital from January 2013 to June 2014 were se- lected and randomly divided into candesartan treatment group（n=27） and routine treatment group（n=15）.28 healthy per- sons with matched age and gender was selected as control group.By enzyme-linked immunosorbent assay,serum copeptin levels in three groups were detected.The routine treatment group and candesartan treatment group was reexam- ined two weeks after treatment. Results The level of serum copeptin in patients with dilated cardiomyopathy was greatly increased compared with the healthy control group with a statistical difference（P〈0.05）.After using candesartan,the level of serum copeptin in candesartan treatment group was significantly decreased compared with that before treatment,the difference was significant （P〈0.05）,but the level of serum copeptin in routine treatment group was indicated a declined tendency compared with that before,the difference was no significant （P〉0.05）. Conclusion The serum eopeptin level in patients with dilated cardiomyopathy and heart failure is in an increase,and candesartan can significantly reduce the serum copeptin level in these patients.